GlassScriptPhysician profile
Razaali Mamdani
NPI 1760587067
$14,064.08
in general payments reported to CMS, 2019-2025
48 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $1,254 · 2021: $2,654 · 2022: $2,501 · 2023: $2,290 · 2024: $2,335 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,361.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,818.84 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,461.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,443.60 | 2021-2025 | |
| Novo Nordisk INC | $1,437.01 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,381.43 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $687.08 | 2022-2025 | |
| Pfizer INC. | $433.79 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.71 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $418.46 | 2019-2023 | Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $358.59 | 2020-2022 | |
| Amgen INC. | $319.00 | 2022-2025 | Otezla, Repatha, Repatha |
| Esperion Therapeutics, INC. | $300.34 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $227.45 | 2019-2022 | |
| Abbott Laboratories | $226.27 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $224.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Razaali Mamdani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.